Holen Sie sich die Stockscreener-App
2.68
2.90%
-0.08
Handel nachbörslich:
2.73
0.05
+1.87%
Schlusskurs vom Vortag:
$2.76
Offen:
$2.81
24-Stunden-Volumen:
1.28M
Relative Volume:
1.05
Marktkapitalisierung:
$305.19M
Einnahmen:
$12.32M
Nettoeinkommen (Verlust:
$-175.72M
KGV:
-1.235
EPS:
-2.17
Netto-Cashflow:
$-141.45M
1W Leistung:
-1.47%
1M Leistung:
-16.77%
6M Leistung:
-33.99%
1J Leistung:
+12.13%
1-Tages-Spanne:
$2.495
$2.81
1-Wochen-Bereich:
$2.27
$2.81
52-Wochen-Spanne:
$1.91
$8.83
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Drops To US$2.81, Yet Insiders May Have Sold Too Early - Simply Wall St
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionFATE - AsiaOne
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 5.7% in September - MarketBeat
Fate Therapeutics Inc (FATE) looking to reclaim success with recent performance - SETE News
Was Fate Therapeutics Inc (FATE)’s session last reading good? - US Post News
Market Recap Check: Fate Therapeutics Inc (FATE)’s Positive Finish at 3.09, Up/Down 5.10 - The Dwinnex
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from Analysts - MarketBeat
Fate Therapeutics Inc [FATE] stock was sold by Xu Yuan at the price of US$2678.0 - Knox Daily
Dimensional Fund Advisors LP Has $6.99 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Holdings of Fate Therapeutics Inc (FATE) are aligned with the stars - SETE News
Fate Therapeutics Inc (FATE) Stock: Heads Or Tails? - Stocks Register
The Fate Therapeutics Inc (FATE) Stock Is Headed for a Correction - US Post News
Market Insight: Fate Therapeutics Inc (FATE)’s Notable Gain, Closing at 3.22 - The Dwinnex
Renaissance Technologies LLC Takes Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Fate Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Can you still get a good price for Fate Therapeutics Inc (FATE) Shares at this point? - US Post News
Fate Therapeutics' SWOT analysis: cell therapy stock poised for pivotal year - Investing.com
Investor’s Toolkit: Key Ratios for Assessing Fate Therapeutics Inc (FATE)’s Performance - The Dwinnex
Perceptive Advisors LLC Purchases New Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
You might want to take a look at Fate Therapeutics Inc (FATE) now - SETE News
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Holdings Lifted by Deerfield Management Company L.P. Series C - MarketBeat
FATE’s Debt-to-Equity Ratio at 0.25: What It Means for Fate Therapeutics Inc’s Future - The InvestChronicle
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bumble Inc. - GlobeNewswire
Fate Trigger The Novita Cinematic Teaser - GameSpot
FTR: Trailer orders remain below expectations - Fleet Equipment Magazine
Should investors be concerned about Fate Therapeutics Inc (FATE)? - US Post News
FendX Provides Corporate Update - Newsfile
Closing Figures: Fate Therapeutics Inc (FATE)’s Negative Finish at 3.87, Down -3.25 - The Dwinnex
Integral Health Asset Management LLC Acquires 650,000 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Acquired by Bank of New York Mellon Corp - Defense World
FTR reports August 2024 trailer orders were below projections - Trucks, Parts, Service
Kaskela Law LLC Announces Shareholder Investigation of Fate - GlobeNewswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.90 Consensus Price Target from Brokerages - MarketBeat
Top investors say Fate Therapeutics Inc (FATE) ticks everything they need - SETE News
E Fund Management Co. Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Technical analysis of Fate Therapeutics Inc (FATE) stock chart patterns - US Post News
Bruce & Co. Inc. Has $984,000 Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference - GlobeNewswire
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? - Yahoo Finance
Acadian Asset Management LLC Increases Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Stake Lifted by Acadian Asset Management LLC - Defense World
Are Smart Investors Making the Right Decision? Fate Therapeutics Inc (FATE) - SETE News
Examining Fate Therapeutics Inc (FATE) more closely is necessary - US Post News
Financial Analysis: Fate Therapeutics Inc (FATE)’s Ratios Unveil Key Insights - The Dwinnex
There is no way Fate Therapeutics Inc (FATE) can keep these numbers up - SETE News
FATE underperforms with a -5.99 decrease in share price - US Post News
Deeper Dive: Understanding Fate Therapeutics Inc (FATE) Through its Various Ratios - The Dwinnex
Bone Degeneration Therapeutics Market Outlook, Growth By Top - openPR
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):